Treatment of focal segmental glomerulosclerosis.

Abstract

The prognosis of untreated patients with focal segmental glomerulosclerosis is poor, as the disease progress to end-stage renal disease in approximately 50--70% of nephrotic patients. Although focal segmental glomerulosclerosis was initially considered to be a steroid-resistant disease, several studies have shown a better responsiveness to more prolonged courses of steroids. For patients with steroid-resistant or -dependent focal segmental glomerulosclerosis, cyclosporine A and cytotoxic agents have shown efficacy in clinical trials. Plasmapheresis or LDL-apheresis may represent a rescue treatment in patients who do not respond to other therapies. The role of other agents used in focal segmental glomerulosclerosis, including azathioprine, mycophenolate mofetil, tacrolimus, pefloxacin or vitamin E is still poorly defined.

• Authors: P Passerini, C Ponticelli
• Journal: Current opinion in nephrology and hypertension (Curr Opin Nephrol Hypertens) Vol. 10 Issue 2 Pg. 189-93 (Mar 2001) ISSN: 1062-4821 [Print] England
• PMID: 11224693 (Publication Type: Journal Article, Review)

Chemical References

• Adrenal Cortex Hormones
• Antineoplastic Agents
• Purines
• Vitamin E
• Pefloxacin
• Cyclosporine
• Tacrolimus

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Blood Component Removal
• Cyclosporine (therapeutic use)
• Drug Resistance
• Glomerulosclerosis, Focal Segmental (drug therapy, therapy)
• Humans
• Immunosorbent Techniques
• Pefloxacin (therapeutic use)
• Purines (biosynthesis)
• Tacrolimus (therapeutic use)
• Vitamin E (therapeutic use)